Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (35)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kinniburgh, D.
Right arrow Articles by Anderson, R.A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kinniburgh, D.
Right arrow Articles by Anderson, R.A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 17, No. 6, 1490-1501, June 2002
© 2002 European Society of Human Reproduction and Embryology

Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men

D. Kinniburgh1, H. Zhu2, L. Cheng2, A.T. Kicman3, D.T. Baird1 and R.A. Anderson4,5

1 Department of Obstetrics and Gynaecology, Centre for Reproductive Biology, University of Edinburgh, Edinburgh, 2 Shanghai Institute of Family Planning Technical Instruction, Shanghai, People's Republic of China, 3 Drug Control Centre, King's College London and 4 MRC Human Reproductive Sciences Unit, Centre for Reproductive Biology, 37 Chalmers Street, Edinburgh EH3 9ET, UK

BACKGROUND: Effective hormonal male contraception requires a high prevalence of spermatogenic suppression, which has proved particularly difficult in Caucasian populations. We have investigated the combination of oral desogestrel with depot testosterone in Caucasian and Chinese men. METHOD: Thirty men in Edinburgh and 36 men in Shanghai received 150 or 300 µg desogestrel p.o. daily for 24 weeks with 400 mg testosterone pellets s.c. on day 1 and at 12 weeks. RESULTS: Eight men withdrew before completing 24 weeks treatment. Testosterone concentrations remained within the normal range. Spermatogenesis was profoundly suppressed in all men. Azoospermia was achieved by a higher proportion of men in the 300 µg desogestrel group: 28/28 men versus 22/31 men (P < 0.05). All Caucasian men in the 150 µg group achieved sperm concentrations of <1x106/ml whereas three men in the Shanghai group maintained sperm concentrations of >3x106/ml. Fifteen men continued on this regimen for a subsequent 24 weeks: all remained azoospermic for the duration of treatment. High-density lipoprotein cholesterol fell by 15% in Caucasian men, but was unchanged in the Chinese men; both groups showed some weight gain. CONCLUSION: This combination of oral desogestrel with depot testosterone maintains physiological testosterone concentrations with consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men and therefore has many of the properties necessary for a contraceptive preparation for men.

Key words: desogestrel/male contraception/progestogen/spermatogenesis/testosterone

5 To whom correspondence should be addressed. E-mail: r.a.anderson{at}hrsu.mrc.ac.uk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Endocr. Rev.Home page
S. T. Page, J. K. Amory, and W. J. Bremner
Advances in Male Contraception
Endocr. Rev., June 1, 2008; 29(4): 465 - 493.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. Y. Liu, R. S. Swerdloff, B. D. Anawalt, R. A. Anderson, W. J. Bremner, J. Elliesen, Y.-Q. Gu, W. M. Kersemaekers, Robert. I. McLachlan, M. C. Meriggiola, et al.
Determinants of the Rate and Extent of Spermatogenic Suppression during Hormonal Male Contraception: An Integrated Analysis
J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1774 - 1783.
[Abstract] [Full Text] [PDF]


Home page
J AndrolHome page
M. J. Walton, N. Kumar, D. T. Baird, H. Ludlow, and R. A. Anderson
7{alpha}-Methyl-19-Nortestosterone (MENT) vs Testosterone in Combination With Etonogestrel Implants for Spermatogenic Suppression in Healthy Men
J Androl, September 1, 2007; 28(5): 679 - 688.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. J. Walton, R. A. L. Bayne, I. Wallace, D. T. Baird, and R. A. Anderson
Direct Effect of Progestogen on Gene Expression in the Testis during Gonadotropin Withdrawal and Early Suppression of Spermatogenesis
J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2526 - 2533.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
K. L. Matthiesson and R. I. McLachlan
Male hormonal contraception: concept proven, product in sight?
Hum. Reprod. Update, July 1, 2006; 12(4): 463 - 482.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
B.M. Brady, J.K. Amory, A. Perheentupa, M. Zitzmann, C.J. Hay, D. Apter, R.A. Anderson, W.J. Bremner, P. Pollanen, E. Nieschlag, et al.
A multicentre study investigating subcutaneous etonogestrel implants with injectable testosterone decanoate as a potential long-acting male contraceptive
Hum. Reprod., January 1, 2006; 21(1): 285 - 294.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. C. Meriggiola, A. Costantino, F. Saad, L. D'Emidio, A. M. Morselli Labate, A. Bertaccini, W. J. Bremner, I. Rudolph, M. Ernst, B. Kirsch, et al.
Norethisterone Enanthate Plus Testosterone Undecanoate for Male Contraception: Effects of Various Injection Intervals on Spermatogenesis, Reproductive Hormones, Testis, and Prostate
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2005 - 2014.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. J. Hay, B. M. Brady, M. Zitzmann, K. Osmanagaoglu, P. Pollanen, D. Apter, F. C. W. Wu, R. A. Anderson, E. Nieschlag, P. Devroey, et al.
A Multicenter Phase IIb Study of a Novel Combination of Intramuscular Androgen (Testosterone Decanoate) and Oral Progestogen (Etonogestrel) for Male Hormonal Contraception
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2042 - 2049.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
B.M. Brady, M. Walton, N. Hollow, A.T. Kicman, D.T. Baird, and R.A. Anderson
Depot testosterone with etonogestrel implants result in induction of azoospermia in all men for long-term contraception
Hum. Reprod., November 1, 2004; 19(11): 2658 - 2667.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
G. Shetty, C. C. Y. Weng, O. U. Bolden-Tiller, I. Huhtaniemi, D. J. Handelsman, and M. L. Meistrich
Effects of Medroxyprogesterone and Estradiol on the Recovery of Spermatogenesis in Irradiated Rats
Endocrinology, October 1, 2004; 145(10): 4461 - 4469.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. I. McLachlan, D. M. Robertson, E. Pruysers, A. Ugoni, A. M. Matsumoto, B. D. Anawalt, W. J. Bremner, and C. Meriggiola
Relationship between Serum Gonadotropins and Spermatogenic Suppression in Men Undergoing Steroidal Contraceptive Treatment
J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 142 - 149.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. C. Meriggiola, A. Costantino, S. Cerpolini, W. J. Bremner, D. Huebler, A. M. Morselli-Labate, B. Kirsch, A. Bertaccini, C. Pelusi, and G. Pelusi
Testosterone Undecanoate Maintains Spermatogenic Suppression Induced by Cyproterone Acetate Plus Testosterone Undecanoate in Normal Men
J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5818 - 5826.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
L. Turner, A. J. Conway, M. Jimenez, P. Y. Liu, E. Forbes, R. I. McLachlan, and D. J. Handelsman
Contraceptive Efficacy of a Depot Progestin and Androgen Combination in Men
J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4659 - 4667.
[Abstract] [Full Text] [PDF]


Home page
J AndrolHome page
M. C. Meriggiola, T. M.M. Farley, and M. T. Mbizvo
A Review of Androgen-Progestin Regimens for Male Contraception
J Androl, July 1, 2003; 24(4): 466 - 483.
[Full Text] [PDF]


Home page
EndocrinologyHome page
S. Ramaswamy, G. R. Marshall, C. R. Pohl, R. L. Friedman, and T. M. Plant
Inhibitory and Stimulatory Regulation of Testicular Inhibin B Secretion by Luteinizing Hormone and Follicle-Stimulating Hormone, Respectively, in the Rhesus Monkey (Macaca mulatta)
Endocrinology, April 1, 2003; 144(4): 1175 - 1185.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
K. L. Matthiesson, D. M. Robertson, H. G. Burger, and R. I. McLachlan
Response of serum inhibin B and pro-{alpha}C levels to gonadotrophic stimulation in normal men before and after steroidal contraceptive treatment
Hum. Reprod., April 1, 2003; 18(4): 734 - 743.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
R. A. Anderson and D. T. Baird
Male Contraception
Endocr. Rev., December 1, 2002; 23(6): 735 - 762.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
R.A. Anderson, Z.M. van der Spuy, O.A. Dada, S.K. Tregoning, P.M. Zinn, O.A. Adeniji, T.A. Fakoya, K.B. Smith, and D.T. Baird
Investigation of hormonal male contraception in African men: suppression of spermatogenesis by oral desogestrel with depot testosterone
Hum. Reprod., November 1, 2002; 17(11): 2869 - 2877.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. A. Anderson, D. Kinniburgh, and D. T. Baird
Suppression of Spermatogenesis by Etonogestrel Implants with Depot Testosterone: Potential for Long-Acting Male Contraception
J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3640 - 3649.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.